Sunshine Biopharma Inc. — Form 8-K
Filed August 28, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Form 8-K Item 5.02 filing dated 2026-08-28 reporting changes to directors, officers, or their compensatory arrangements effective 2026-08-25. The filing document references exist but specific names, amounts, equity grants, cash compensation, dates of departure/appointment, and contractual terms are not disclosed in the provided filing header or metadata. Full details require review of the actual 8-K document (sunshine_8k.htm).
Why this rating
Without concrete compensation figures or officer names, cannot assess materiality. At $7.1M market cap, executive changes could be significant if major, but absent specifics, this appears routine Item 5.02 disclosure.
Extracted items
See more from August 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.